Rheumatology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Rheumatology Search

Rheumatology

Rheumatology

Home News Diseases Conferences Special Reports Multimedia

Fat mass reduces response to TNF-α blockers in patients with ankylosing spondylitis

21 hours ago

Higher body fat content at baseline in patients with ankylosing spondylitis (AS) is likely to weaken response to treatment with tumour necrosis factor-α (TNF-α) blockers, measured by the Ankylosing Spondylitis Disease Activity Score containing C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), suggests a recent study.

5-year etanercept therapy provides positive CV effects in PsA patients

Yesterday

Etanercept therapy for a period of 5 years leads to small changes in serum lipid concentrations, which are inversely correlated with inflammatory markers, according to a recent study. Other cardiovascular disease (CVD) risk factors remain stable.

Two-year tocilizumab regimen shows potential in early RA

Audrey Abella, 6 days ago

The interleukin-6 receptor-alpha inhibitor tocilizumab alone or in combination with methotrexate demonstrated clinical benefit after 2 years of treatment in methotrexate-naïve patients with early rheumatoid arthritis (RA), according to the FUNCTION* trial.

Dactylitis, enthesitis, anterior uveitis occur less frequently in IBD-SpA

14 Sep 2017

Compared with other types of spondyloarthritis (SpA), SpA associated with inflammatory bowel disease (IBD-SpA) has significantly less frequency of dactylitis, enthesitis and anterior uveitis (AU), a recent study has found.

Oral contraceptives protective against rheumatoid arthritis

13 Sep 2017

Oral contraceptives may cut the risk of developing rheumatoid arthritis (RA), especially anticitrullinated protein antibodies (ACPA)-positive RA, a study has found. Furthermore, long duration of OC use protects against the risk of both ACPA-positive and ACPA-negative RA.

Presence of rheumatoid factor tied to 10-year cardiovascular disease in RA patients

07 Sep 2017

The presence of rheumatoid factor (RF) rather than anticyclic citrullinated peptide antibodies (anti-CCP) may predict 10-year cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA), a recent study has found.

The ESCEO algorithm for the management of knee osteoarthritis (OA) and the role of symptomatic slow-acting drugs for OA (SYSADOAs)

03 Apr 2017

At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.

Systemic sclerosis-related pulmonary hypertension in an era of new therapies

07 Mar 2017

At the 17^th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.

Chronic Pain Control: What's Adequate and Appropriate?

18 Aug 2016

During the combined meeting of the 46^th Malaysian Orthopaedic Association Annual General Meeting/Annual Scientific Meeting and the 10th ASEAN Arthroplasty Association Meeting, Dr Joseph Pergolizzi spoke on the importance of chronic pain control and appropriate strategies to achieve this. Highlights of his presentation are summarized below.

Protecting Bones After Menopause - An Expert Opinion Interview on Calcium & Vitamin D

09 Oct 2015

Calcium and vitamin D play a major role in the prevention and treatment of osteoporosis. In this exclusive interview with MIMS Doctor, Dr Yeap Swan Sim talks about the importance of calcium and vitamin D in bone health, as well as the current status of these micronutrients in local postmenopausal women.

Denosumab in Treatment of Osteoporosis in Postmenopausal Women at Increased Risk of Fracture

13 May 2015

Recently, MIMS Doctor sat down with Associate Professor Dr Sabarul Afian Mokhtar to get his perspectives on the use of monoclonal antibody for the treatment of postmenopausal osteoporosis (PO) and also important learning from the International Osteoporosis Foundation (IOF) Regionals 5th Asia-Pacific Osteoporosis Meeting. Highlights from the interview are presented here.

Belimumab: Novel biologic DMARD for the treatment of systemic lupus erythematosus

Naomi Adam, 01 Feb 2014

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.

ABT-981 disappoints in hand osteoarthritis trial

Jackey Suen, 07 Jul 2017

The experimental drug ABT-981 fails to show significant improvements in pain and joint symptoms compared with placebo in patients with hand osteoarthritis (OA), according to a phase IIa trial presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held in Madrid, Spain.

Tofacitinib effective in psoriatic arthritis patients with inadequate response to conventional synthetic DMARDs

Elaine Tan, 29 Jun 2017

Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).

ICOS ligand blockade a promising approach for the treatment of lupus arthritis

Dr. Joseph Delano Fule Robles, 27 Jun 2017

AMG-557, an inducible T-cell costimulator (ICOS) ligand inhibitor, showed efficacy and safety in a randomized multicentre trial that included patients with lupus arthritis from eight centres in the US, France, Malaysia and Germany.

Injustice and low socioeconomic status impact fibromyalgia severity

Christina Lau, 26 Jun 2017

Feelings of injustice and low socioeconomic status can have a significant impact on disease severity in patients with fibromyalgia, according to data from a large survey presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.

Dekavil shows initial signs of safety and efficacy in rheumatoid arthritis

Jackey Suen, 23 Jun 2017

The fully-human immunocytokine dekavil (also known as F8-IL10) has demonstrated signs of safety and efficacy in patients with active rheumatoid arthritis (RA) in a phase I study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017.

IL-6 receptor antibody efficacious for rheumatoid arthritis nonresponsive to methotrexate

Dr. Joseph Delano Fule Robles, 23 Jun 2017

Vobarilizumab, a nanobody consisting of an anti-interleukin 6 (IL-6) receptor domain developed for the treatment of rheumatoid arthritis (RA), is shown to be safe and efficacious in RA patients with inadequate response to methotrexate in a study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.